

Javier Ampuero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6382588/publications.pdf>

Version: 2024-02-01

105
papers

2,971
citations

172457

29
h-index

189892

50
g-index

113
all docs

113
docs citations

113
times ranked

4263
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159
2	Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	12.8	156
3	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
4	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018, 69, 1335-1348.	3.7	121
5	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
6	Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated With Survival of Patients With Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 1483-1489.	1.3	108
7	Development and Validation of Hepamet Fibrosis Scoring Systemâ€”A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
8	Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. <i>World Journal of Gastroenterology</i> , 2013, 19, 7327.	3.3	103
9	Review article: <scp>HCV</scp> genotype 3 â€” the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	3.7	103
10	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
11	Sofosbuvir/velpatasvir for 12â€”weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93
12	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
13	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	4.4	83
14	The effects of metabolic status on nonâ€”alcoholic fatty liver diseaseâ€”related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	3.7	70
15	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	3.7	66
16	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
17	Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 10-6.	0.3	64
18	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59

#	ARTICLE	IF	CITATIONS
19	Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy. PLoS ONE, 2012, 7, e49279.	2.5	55
20	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
21	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clinical Microbiology and Infection, 2016, 22, 839-845.	6.0	42
22	Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. Journal of Viral Hepatitis, 2017, 24, 304-311.	2.0	40
23	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 291-295.	2.8	36
24	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 718-725.	2.8	34
25	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 31421.	3.3	33
26	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS ONE, 2018, 13, e0191805.	2.5	33
27	Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Annals of Hepatology, 2013, 12, 420-430.	1.5	32
28	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World Journal of Hepatology, 2015, 7, 1105.	2.0	31
29	Role of diabetes mellitus on hepatic encephalopathy. Metabolic Brain Disease, 2013, 28, 277-279.	2.9	30
30	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. World Journal of Gastroenterology, 2016, 22, 10064.	3.3	28
31	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver International, 2017, 37, 212-223.	3.9	28
32	Wilson's disease: Revisiting an old friend. World Journal of Hepatology, 2021, 13, 634-649.	2.0	28
33	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1611-1618.	2.8	25
34	Assessing cardiovascular risk in hepatitis C: An unmet need. World Journal of Hepatology, 2015, 7, 2214.	2.0	22
35	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clinical Gastroenterology and Hepatology, 2017, 15, 945-949.e1.	4.4	22
36	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2017, 24, 226-237.	2.0	22

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Virus Clearance by Direct-Acting Antiviral Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEP-CAR Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00203.	2.5	21
38	Stratification of patients in NASH clinical trials: A pitfall for trial success. <i>JHEP Reports</i> , 2020, 2, 100148.	4.9	20
39	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 389-396.	0.3	20
40	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. <i>Scientific Reports</i> , 2022, 12, 3418.	3.3	19
41	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 74-80.	3.7	18
42	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-363.	1.5	18
43	Diagnostic accuracy of <sc>SCCA</sc> and <sc>SCCA</sc>â€lgM for hepatocellular carcinoma: A metaâ€nalysis. <i>Liver International</i> , 2018, 38, 1820-1831.	3.9	18
44	Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 125-135.	0.3	17
45	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 519-530.	3.7	17
46	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2022, 76, 11-24.	3.7	16
47	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	3.7	15
48	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	3.7	15
49	Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 845-857.	2.2	14
50	Bacterial antigen translocation and age as BMIâ€independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	3.9	14
51	Long nonâ€ncoding <sc>RNA <i>H19</i></sc> as a biomarker for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1410-1422.	3.9	14
52	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsyâ€proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	3.9	13
53	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1238-1247.	0.4	12
54	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-63.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015, 68, 56-60.	3.1	11
56	An Experimental DUAL Model of Advanced Liver Damage. <i>Hepatology Communications</i> , 2021, 5, 1051-1068.	4.3	11
57	Stanozolol-induced bland cholestasis. <i>Gastroenterología Y Hepatología</i> , 2014, 37, 71-72.	0.5	10
58	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015, 16, 297-300.	4.1	10
59	Remission maintained by monotherapy after biological+immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 112-118.	2.8	10
60	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016, 17, 1587-1594.	1.3	10
61	Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 128-142.	0.5	10
62	Looking for a new name for Non-alcoholic fatty liver disease in Spanish: Esteatosis Hepática Metabólica (EHmet). <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 161-163.	0.3	10
63	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , 2016, 22, 5285.	3.3	10
64	Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. <i>Liver International</i> , 2022, 42, 1783-1792.	3.9	10
65	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774341.	3.2	9
66	Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. <i>Gut</i> , 2022, 71, 2138-2140.	12.1	9
67	New technologies " new insights into the pathogenesis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2016, 31, 1259-1267.	2.9	8
68	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2022, 117, 138-146.	0.4	8
69	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , 2017, 9, 697.	2.0	8
70	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. <i>Journal of Gastroenterology</i> , 2022, 57, 357-371.	5.1	8
71	Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in Clinical Practice. <i>Gastroenterology</i> , 2014, 146, 887-890.	1.3	7
72	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , 2021, 41, 95-104.	3.9	7

#	ARTICLE	IF	CITATIONS
73	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 667354.	4.8	7
74	Meta-analysis: pegylated interferon α 2a achieves higher early virological responses than α 2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	3.7	6
75	Solving doubts about L-carnithine L-aspartate for overt hepatic encephalopathy: Whom and how to treat. <i>Hepatology</i> , 2018, 67, 476-478.	7.3	6
76	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 356-362.	1.4	6
77	Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 921-930.	3.9	5
78	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	2.8	5
79	Editorial: looking for patients at risk of cirrhosis in the general population "many needles in a haystack. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 692-694.	3.7	4
80	Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 223-227.	0.3	4
81	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	2.2	4
82	General Overview About the Current Management of Nonalcoholic Fatty Liver Disease. <i>Clinical Drug Investigation</i> , 2022, 42, 39-45.	2.2	4
83	Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain. <i>Annals of Hepatology</i> , 2018, 17, 864-870.	1.5	3
84	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 427-433.	0.3	3
85	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.4	3
86	Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. <i>World Journal of Virology</i> , 2021, 10, 301-311.	2.9	3
87	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. <i>Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterología Y Hepatología</i> , 2022, 45, 724-734.	0.5	3
88	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 699.	1.0	2
89	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014, 60, S139.	3.7	2
90	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	2.5	2

#	ARTICLE	IF	CITATIONS
91	Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 181-186.	3.6	2
92	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 301-307.	0.3	2
93	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 270-274.	0.3	2
94	LPAC syndrome associated with deletion of the full exon 4 in a ABCB4 genetic mutation in a patient with hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 544-7.	0.3	2
95	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». <i>Gastroenterología Y Hepatología</i> , 2023, 46, 236-247.	0.5	2
96	Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 20-25.	0.5	1
97	Acute-on-chronic liver failure: A time to step forward. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 397-398.	0.3	1
98	One-step diagnosis. A key tool for the elimination of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 513-514.	0.3	1
99	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 8343-8356.	3.3	1
100	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. <i>Clinical and Translational Medicine</i> , 2021, 11, e275.	4.0	0
101	COVID-19 and the liver: The chicken or the egg dilemma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 555.	0.3	0
102	Reply to: «The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD». <i>Journal of Hepatology</i> , 2021, 74, 971-972.	3.7	0
103	Entwicklung und Validierung des NAFLD Cirrhosis Score (NCS) zur Separierung von fortgeschrittener Fibrose und Zirrhose. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.5	0
104	The Spectrum of NAFLD: From the Organ to the System. , 2020, , 1-10.		0
105	Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2022, 117, 819-819.	0.4	0